Southeast Asset Advisors LLC Has $1.19 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Southeast Asset Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 4.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,746 shares of the biopharmaceutical company’s stock after selling 2,035 shares during the quarter. Southeast Asset Advisors LLC’s holdings in Pfizer were worth $1,187,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in Pfizer during the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Pfizer during the fourth quarter worth about $274,694,000. Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Pfizer by 79.5% during the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after purchasing an additional 4,938,209 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $22.99 on Monday. Pfizer Inc. has a 12 month low of $22.28 and a 12 month high of $31.54. The stock has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $25.87 and its 200 day moving average is $26.72.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PFE shares. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.